Harmony Biosciences/$HRMY
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Harmony Biosciences
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
- Ticker
- $HRMY
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 293
- Headquarters
- Plymouth Meeting, United States
- Website
- www.harmonybiosciences.com
HRMY Metrics
BasicAdvanced
$1.9B
10.74
$3.02
0.98
-
Price and volume
Market cap
$1.9B
Beta
0.98
52-week high
$43.49
52-week low
$25.90
Average daily volume
1.1M
Financial strength
Current ratio
3.443
Quick ratio
3.31
Long term debt to equity
0.125
Total debt to equity
0.144
Interest coverage (TTM)
16.99%
Profitability
EBITDA (TTM)
244.697
Gross margin (TTM)
74.03%
Net profit margin (TTM)
18.05%
Operating margin (TTM)
22.17%
Effective tax rate (TTM)
23.33%
Revenue per employee (TTM)
$3,380,000
Management effectiveness
Return on assets (TTM)
10.21%
Return on equity (TTM)
18.73%
Valuation
Price to earnings (TTM)
10.736
Price to revenue (TTM)
1.902
Price to book
1.78
Price to tangible book (TTM)
1.91
Price to free cash flow (TTM)
6.926
Free cash flow yield (TTM)
14.44%
Free cash flow per share (TTM)
4.688
Growth
Revenue change (TTM)
19.79%
Earnings per share change (TTM)
-4.53%
3-year revenue growth (CAGR)
22.22%
3-year earnings per share growth (CAGR)
6.96%
What the Analysts think about HRMY
Analyst ratings (Buy, Hold, Sell) for Harmony Biosciences stock.
Analyst projections of the future price of Harmony Biosciences stock.
Bulls say / Bears say
WAKIX continues to deliver growth: third-quarter revenue rose 12% year on year to $268.9 million, with 400 net patient additions, and Harmony reaffirmed its $1.0–$1.04 billion full-year revenue guidance. (Harmony Biosciences)
There is room to reach more patients: Harmony estimates that fewer than half of the 170,000 people in the US living with narcolepsy are diagnosed, while brand treatment penetration is about 20%. (Harmony Biosciences)
Pitolisant GR could extend the franchise with a differentiated formulation that allows patients to start at a therapeutic dose without titration. Its FDA decision date is April 2027, giving the company a potential product catalyst next year. (Harmony Biosciences)
WAKIX’s generic protection remains exposed to litigation: a ruling in the remaining AET case is expected around February 2027, and an adverse result could bring generic competition forward. Harmony says it has settled with six of seven generic challengers, leaving this dispute unresolved. (Harmony Biosciences, Investing.com)
Costs are rising faster than sales: product costs increased 35% year on year as a share of revenue rose from 25% to 30%, largely due to new royalties. Third-quarter net income fell to $48.2 million from $50.9 million. (Harmony Biosciences)
A new narcolepsy competitor, ORZEYFUL, is entering the market and could make it harder for WAKIX to keep adding patients. Harmony has highlighted WAKIX’s broader use and non-scheduled status, but competition may still weigh on growth. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2026.
HRMY Financial Performance
Revenues and expenses
HRMY Earnings Performance
Company profitability
Upcoming events
No upcoming events
HRMY News
AllArticlesVideos
Funds containing HRMY
AllUSDEURGBP
Fund name | Fund size | $HRMY weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.17% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.17% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.17% |
iShares Ageing Population$AGED | $953M | 0.15% |
iShares Ageing Population£AGES | $953M | 0.15% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.